FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Among 5069 eligible respondents, 3,606 (71.1%) reported trusting CIP a lot, 1,186 (23.4%) some, 219 (4.3%), a little, and 58 (1.1%) not at all (Figure 1). 2,655 (52.4%) men received PSA-screening. The degree of trust in CIP was strongly associated with the likelihood of receiving PSA-screening: among men who reported a lot of trust, 54.9% underwent screening, 48.6% some trust, 38.4% a little trust, and 27.6% among men not at all trusting their physician (trend p < 0.0001). The degree to which men trusted CII was also associated with having received PSA-screening (p =0.005), albeit with an insignificant trend (p =0.07). After multivariable adjustment, these significant results persisted for degree of CIP trust (a lot vs some OR 0.80, 95%CI 0.66-0.97; 0 vs. a little OR 0.61, 95%CI 0.41-0.90; vs. not at all OR 0.33, 95% CI 0.15-0.73), but not for trust in CII (Table 1).
The authors concluded that the level of trust an individual has in their physician is strongly associated with undergoing PSA-screening. As rationale implementation of PSA screening requires shared decision making, the level of physician trust has implications for the dissemination of PSA-screening guidelines.
Presented by: Zachary Klaassen, MD, University Health Network/Princess Margaret Cancer Centre
Co-Author: Christopher J.D. Wallis, Hanan Goldberg, Thenappan Chandrasekar, Neil E. Fleshner, Antonio Finelli, Girish S. Kulkarni, Toronto, Canada, Raj Satkunasivam, Houston, TX
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA